Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài: " Growth factors in idiopathic pulmonary fibrosis: relative roles. | Available online http content 3 1 13 Review Growth factors in idiopathic pulmonary fibrosis relative roles Jeremy T Allen and Monica A Spiteri Centre for Cell and Molecular Medicine Keele University School of Medicine North Staffordshire Hospital Stoke-on-Trent UK Correspondence Dr JT Allen Centre for Cell and Molecular Medicine Keele University School of Medicine North Staffordshire Hospital Thornburrow Drive Hartshill Stoke-on-Trent ST4 7QB UK. Tel 44 1782 555452 fax 44 1782 747319 e-mail Received 5 September 2001 Accepted 24 September 2001 Published 28 November 2001 Respir Res 2002 3 13 2002 BioMed Central Ltd Print ISSN 1465-9921 Online ISSN 1465-993X Abstract Treatment of idiopathic pulmonary fibrosis patients has evolved very slowly the fundamental approach of corticosteroids alone or in combination with other immunosuppressive agents has had little impact on long-term survival. The continued use of corticosteroids is justified because of the lack of a more effective alternative. Current research indicates that the mechanisms driving idiopathic pulmonary fibrosis reflect abnormal dysregulated wound healing within the lung involving increased activity and possibly exaggerated responses by a spectrum of profibrogenic growth factors. An understanding of the roles of these growth factors and the way in which they modulate events at cellular level could lead to more targeted therapeutic strategies improving patients quality of life and survival. Keywords alveolar epithelial cell apoptosis growth factor idiopathic pulmonary fibrosis myofibroblast Introduction Idiopathic pulmonary fibrosis IPF is clinically a restrictive lung disease that characteristically progresses relentlessly to death from respiratory failure. Median survival of newly diagnosed patients with IPF is about 3 years similar to that of clinical stage 1b non-small cell lung cancer. The quality of life for IPF patients is also poor. Despite this there
